Chapter 1
The Pandemic That Could Have Been Prevented
In February 2020, over dinner with a dozen infectious disease experts, Bill Gates realized COVID-19 would become a global catastrophe. Despite China's unprecedented lockdown in Wuhan, the experts confirmed his fears: with airborne transmission making this virus highly contagious, containment was unlikely. Millions would soon be infected worldwide. When Gates asked why governments weren't acting more decisively, researcher Keith Klugman simply replied: "They should be." This moment crystallized what would become Gates' mission-to ensure humanity never faces such unpreparedness again.
Gates' passion for fighting infectious diseases began in 1997 when he and Melinda read about millions of children dying annually from diarrheal diseases. This revelation led him to dive deep into global health, consuming eighty-one textbooks and articles provided by Dr. Bill Foege. Today, his foundation's work has helped dramatically reduce childhood mortality worldwide. Yet despite these advances, COVID-19 revealed how vulnerable we remain to novel pathogens. With international travel increasing from 25 million arrivals in 1950 to 1.4 billion in 2019, and urban expansion encroaching on wildlife habitats, the risk of pandemics is higher than ever. As Gates' foundation colleague Nathan Myhrvold warned years before COVID: we were doing almost nothing to prepare for either natural or engineered pandemics.
Chapter 2
Learning from Our COVID Response: The Good, Bad, and Ugly
The countries that fared best during COVID-19 acted quickly with three key measures: extensive testing, isolation of positive cases and their contacts, and strong border management. Australia, Vietnam, New Zealand, and South Korea demonstrated that early, decisive action saved thousands of lives. Meanwhile, the United States' response in 2020 was disastrous-the White House downplayed the threat, federal agencies refused to share data, and the CDC provided politically influenced guidance. Most egregious was America's testing failure: insufficient capacity, delayed results, and no centralized system to prioritize testing or record outcomes.
Despite these failures, countless individuals performed heroic work. Shilpashree A.S. in Bengaluru, India spent five months conducting COVID tests in a protective booth, sacrificing physical contact with her family. Thabang Seleke volunteered for vaccine trials in Soweto, South Africa. Sikander Bizenjo founded Balochistan Youth Against Corona in Pakistan, training over 150 young people and providing aid to thousands of families. Healthcare workers worldwide risked their lives, with over 115,000 losing their lives by May 2021.
The pandemic taught us to expect viral variants, surges, and breakthrough cases. While early in the pandemic scientists believed COVID mutations wouldn't cause major problems, the Delta variant proved otherwise with dramatically increased transmissibility, followed by the even faster-spreading Omicron. We also learned that good science is messy and evolves-the CDC's changing mask guidance wasn't incompetence but the reality of managing novel threats with imperfect data in constantly changing conditions.
Perhaps most importantly, we learned that innovation doesn't happen overnight-it requires years of patient scientific work, funding, smart policies, and entrepreneurial drive. COVID would have been far worse without previous investments in mRNA and viral vector vaccine technologies. The pandemic showcased numerous innovations while teaching us valuable lessons about virus transmission. It highlighted that while the private sector excels at translating research into products, government plays a crucial role by funding basic research and creating enabling policies.
Despite developing safe vaccines in record time, too few people in poor countries received them. More concerning is our failure to seriously prepare for pandemics. Unlike fires, natural disasters, and wars-where governments have experts, resources, tools, and regular drills-pandemic preparation has been virtually nonexistent. What we need is a dedicated global corps focused on spotting diseases early, responding effectively, and measuring our readiness.
Chapter 3
Creating a Pandemic Prevention Team: The GERM Squad
Just as Rome created the first permanent firefighting team in 6 CE after a devastating fire, we need a global pandemic equivalent. Today's firefighting infrastructure-with 311,000 full-time firefighters across 30,000 U.S. departments alone-demonstrates how societies recognize community protection transcends individual responsibility. While fires remain local, diseases spread worldwide, requiring a global response team.
Unlike Hollywood portrayals of pandemic response, reality lacks the coordinated agency that acts swiftly and decisively. While many organizations respond to outbreaks, their efforts largely depend on volunteers, and even the WHO has minimal funding and personnel dedicated specifically to pandemics. No existing organization has the necessary size, scope, resources, and mandate for effective global outbreak detection and response.
The proposed GERM (Global Epidemic Response and Mobilization) team would employ approximately 3,000 full-time experts in epidemiology, genetics, drug development, data systems, diplomacy, rapid response, logistics, modeling, and communications. Managed by the WHO for global credibility, this diverse workforce would operate from national public health institutes worldwide with some staff at WHO offices.
GERM would monitor potential outbreaks, analyze early data, coordinate modeling efforts, advise on priority vaccines, and create common response protocols. Working diplomatically with local experts rather than supplanting them, GERM would support countries needing additional expertise while organizing "germ games"-simulated outbreak exercises-to identify and address weaknesses in the global response system.
The team would cost about $1 billion annually-less than one-thousandth of global defense spending-and would be a bargain considering the trillions COVID has cost. Unlike treating patients directly, GERM would coordinate and complement clinical experts by focusing on surveillance, modeling and other specialized functions that currently fall through the cracks of our fragmented global health system.
Chapter 4
Building Better Disease Detection Systems
Effective disease surveillance is essential for preventing pandemics, yet remains woefully underfunded globally. The challenge isn't finding a needle in a haystack, but identifying the deadliest needles in a mountain of somewhat duller ones-distinguishing between routine illnesses and potential catastrophes.
Disease surveillance operates through two main approaches. Passive surveillance relies on healthcare systems reporting aggregated data on reportable diseases to public health agencies and global databases, allowing analysts to identify suspicious patterns like unusual pneumonia clusters in healthcare workers. Active surveillance involves proactively seeking out diseases by meeting potential patients where they are-like polio workers checking communities for symptoms while vaccinating.
Some countries have developed innovative approaches: Japan employs postal workers for health monitoring, Vietnam trains teachers to report when multiple children have similar symptoms, and pharmacists track spikes in medicine sales. Environmental surveillance, such as testing sewage for pathogens, provides another early warning system that has proven effective for polio and COVID detection, allowing officials to prepare for case surges before they appear in clinical tests.
While rich countries record nearly all births and deaths, many low- and middle-income countries rely on infrequent household surveys that yield imprecise data with years of delay. Only 44 percent of African births are registered compared to over 90 percent in Europe and America. In low-income countries, just one in ten deaths is recorded, with cause of death rarely noted. This invisibility extends to disease detection-by late 2021, only 1 percent of COVID infections in Africa were being detected versus 37 percent in Europe.
The Seattle Flu Study demonstrates how innovative surveillance can transform outbreak detection. Despite its name, the study tested for 26 different respiratory pathogens, collecting samples from volunteers at public kiosks and hospitals, mapping positive cases in real-time and sequencing viral genomes to understand transmission patterns. When COVID emerged in early 2020, the team pivoted quickly, providing up to 25% of all testing in King County and sequencing almost 4,000 viral genomes-more than half of Washington state's sequences that year.
Disease modelers, once obscure specialists, gained prominence during the pandemic as their predictions became crucial for understanding COVID's spread. Different modeling teams answer different questions: South African researchers determined Omicron's reinfection capabilities, while London School of Hygiene teams quantified the impact of masks and social distancing. Disease modeling is similar to weather forecasting-more accurate in the short term than long term-but relies heavily on quality data.
To prevent future pandemics, we need a comprehensive disease surveillance strategy. Every community should detect outbreaks within seven days, report and begin investigation within one more day, and implement control measures within another week. We must expand efforts to understand causes of death in both adults and children, develop innovative mass testing capabilities, dramatically expand genetic sequencing, and continue investing in computer modeling with better data and constant feedback to improve accuracy.
Chapter 5
Protecting People When Outbreaks Begin
When facing a pandemic, empowering people with choices about how to protect themselves is crucial, even when scientific consensus isn't always embraced. Nonpharmaceutical interventions (NPIs) become our most important early tools before treatments and vaccines are available.
The irony of effective NPIs is that their success makes them appear unnecessary. Cities and countries that implemented measures early saw dramatically lower death rates than those that delayed. St. Louis demonstrated this both in 2020 and during the 1918 pandemic, when its early interventions resulted in death rates far lower than places like Philadelphia that waited. Similarly, Denmark and Norway's strict early lockdowns prevented thousands of deaths compared to Sweden's more relaxed approach. Studies estimate NPIs prevented nearly half a billion COVID infections in just the first months of 2020.
School closures were one of the most contentious pandemic measures. By April 2020, nearly 95 percent of schools worldwide had shut their doors. The pandemic exposed that remote education cannot replace classroom learning for young children. Many students lacked internet access, and even those with access found the experience less engaging. With vaccines, testing, masks, distancing, and better ventilation, long-term closures should be avoidable in future outbreaks similar to COVID.
While masks provide universal protection, the effectiveness of other non-pharmaceutical interventions varies by location and context. Lockdowns clearly reduce transmission, but compliance depends heavily on socioeconomic factors. Cell phone data revealed that before lockdowns, wealthy Americans were most mobile, but afterward, this reversed-poorer people continued moving about because they couldn't work remotely or use delivery services.
In fall 2020, fears of a "twindemic" of flu and COVID overwhelming healthcare systems proved unfounded. Flu cases dropped an astonishing 99 percent between the 2019-20 and 2020-21 seasons. One strain, B/Yamagata, hadn't been detected worldwide since April 2020. This dramatic decline demonstrated that non-pharmaceutical interventions, combined with existing immunity and vaccinations, dramatically reduced flu transmission.
Contact tracing, though unfamiliar to many during COVID, has been crucial in fighting diseases like smallpox, Ebola, and tuberculosis. COVID's transmission pattern made traditional contact tracing inefficient, as about 80% of infections came from just 10% of cases. Some countries tried "backward contact tracing"-identifying who infected the patient rather than just who they might have infected-finding it prevented 2-3 times more cases by identifying superspreaders.
Early COVID advice focused on handwashing and surface cleaning, but we now know airborne transmission is far more significant. The virus can linger in air longer and travel farther than initially thought. Simple ventilation improvements make a substantial difference-schools that opened windows and used fans saw 30% fewer COVID cases, while those adding air filters had 50% fewer cases.
Perhaps most surprising is how cheap and effective masks are. Their use dates back to 1910, when physician Wu Lien-teh successfully deployed them during a pneumonic plague outbreak in China with 100% fatality rates. Despite their proven effectiveness, mask resistance in America has remained surprisingly consistent from the 1918 flu pandemic to COVID-19. Japan's early masking adoption helped keep excess deaths extraordinarily low at 70 per million by late 2021 (compared to 3,200 per million in the US).
Chapter 6
Accelerating Treatment Development
In the early days of COVID-19, misinformation about treatments spread rapidly, with the WHO battling what they called an "infodemic" of false cures ranging from black pepper to vodka. While many hoped for quick therapeutic breakthroughs before vaccines arrived, effective treatments emerged more slowly than expected.
By summer 2020, dexamethasone emerged as the first significant treatment success, reducing mortality in hospitalized patients by nearly a third by suppressing the immune system's potentially deadly overreaction to the virus. This inexpensive steroid saved an estimated one million lives globally by March 2021, though it required careful timing to avoid suppressing immune response too early.
Monoclonal antibodies faced significant limitations despite their promise: they required specialized infusion facilities lacking in developing countries, had to be administered early in the disease course, and lost effectiveness against new variants. By late 2021, researchers shifted focus to more practical treatments-particularly oral antiviral drugs. Merck developed molnupiravir, which significantly reduced hospitalization risk for high-risk patients. Even more impressive was Pfizer's Paxlovid, which when administered early with a drug prolonging its effects, reduced severe illness or death risk by nearly 90 percent.
Even with rapid vaccine development, therapeutics remain essential during outbreaks. In future epidemics, even if vaccines are developed within 100 days, distribution takes time, especially for multi-dose regimens. During this gap, effective treatments can save countless lives. Therapeutics also address long-term effects like "long COVID," help those who refuse vaccination, treat breakthrough cases, and reduce hospital strain.
Small-molecule drugs offer distinct advantages during outbreaks. With simple chemical structures (like aspirin's C9H8O4), they're easy to manufacture, can be taken orally since they resist digestive breakdown, and typically have long shelf lives at room temperature. By contrast, large-molecule drugs like monoclonal antibodies are 100,000 times larger than aspirin, require injection or IV administration by medical personnel, need complex manufacturing using live cells, and cost significantly more to produce at scale.
Beyond drugs, supportive tools like medical oxygen are critical during respiratory outbreaks. According to WHO, about 15% of COVID patients needed supplemental oxygen, yet only 15% of health facilities in developing countries had oxygen equipment, with just half of that functioning properly. Bernard Olayo, after witnessing children die from pneumonia due to oxygen shortages in Kenya, founded Hewatele ("abundant air") to address this crisis. His organization built oxygen plants at busy hospitals and implemented a "milkman model" for cylinder delivery to remote facilities, cutting oxygen prices in Kenya by 50% and reaching 35,000 patients.
For future outbreaks, we need expanded libraries of drug compounds that can be rapidly screened against new pathogens. Priority should go to developing pan-family and broad-spectrum therapies effective against multiple viral infections, particularly those with pandemic potential. Boosting innate immunity-the body's immediate defense system-could help stop infections before they take hold. Advanced technologies like "lung on a chip" devices allow researchers to study drug-pathogen-cell interactions, while AI and machine learning help identify pathogen vulnerabilities and promising compounds.
Chapter 7
The Vaccine Revolution
The development of multiple successful COVID vaccines in roughly a year was nothing short of miraculous. Historically, vaccine candidates have only a 6 percent probability of technical and regulatory success-meaning that out of 100 candidates, only 6 typically make it to approval. COVID vaccines defied these odds, partly because the virus's spike protein makes a relatively easy target.
The truly remarkable aspect of COVID vaccines wasn't just their creation but their unprecedented speed. Typically, vaccine development takes 6-20 years, with up to 9 years just to prepare for clinical testing. Before COVID, the fastest vaccine ever developed took four years-Maurice Hilleman's mumps vaccine in 1967. By consolidating development stages without sacrificing safety, COVID vaccines shattered this record, with Pfizer-BioNTech's vaccine approved just a year after the first cases were identified.
mRNA vaccines represent a revolutionary approach that emerged after decades of painstaking research. Unlike conventional vaccines that use weakened or dead viruses, mRNA vaccines deliver instructions that teach cells to produce proteins matching shapes on the target virus, triggering immune response without introducing the virus itself. This approach allows vaccine development in weeks rather than years.
Katalin Kariko pioneered this work despite numerous setbacks, eventually partnering with Drew Weissman and later joining BioNTech. When COVID hit, companies like Moderna and BioNTech/Pfizer rapidly developed effective vaccines, with mRNA vaccines becoming dominant globally-accounting for 96% of U.S. vaccinations and 100% in Japan by late 2021.
Producing billions of pandemic vaccine doses requires overcoming massive manufacturing hurdles. Second-source deals-where companies share not just recipes but knowledge, personnel and biological samples-proved remarkably effective during COVID. AstraZeneca alone signed deals with twenty-five factories across fifteen countries, while partnerships with manufacturers like Serum Institute of India produced billions of affordable doses.
COVID vaccine distribution revealed stark global inequities-by late 2021, while over half the world's population had received at least one dose, only 8 percent of people in low-income countries were vaccinated. Young, healthy people in wealthy nations often received vaccines before vulnerable populations in poorer countries. Rather than relying on wealthy nations to share limited supplies (which rarely happens at sufficient scale), we must focus on producing enough doses for everyone.
Creating affordable vaccines for developing countries requires innovation beyond initial discovery. When pharmaceutical companies develop vaccines, they naturally price them for wealthy markets to recoup costs. The solution is working with manufacturers in developing countries to create equivalent but lower-cost versions. The Gates Foundation has championed this approach, helping reduce pentavalent vaccine prices from $3.50 to under $1 per dose, increasing global coverage sixteen-fold since 2005.
Delivering vaccines to remote areas presents enormous logistical challenges. Most vaccines must maintain strict temperature control (2-8C) throughout a complex journey-from factory through national, regional, district, and community facilities before reaching patients. Health workers who travel the "last mile" need precision and stamina, often walking long distances while managing complex preparation procedures and record-keeping. Promising developments like micro-needle patches could eventually make vaccines easier and safer to deliver everywhere.
While current vaccines primarily prevent severe illness and death, the ideal vaccine would prevent infection entirely, eliminating transmission completely. The measles vaccine achieves this with 97% protection against infection after two doses. For respiratory diseases like COVID, we need delivery methods that target where viruses enter the body-through the mucus membranes. Nasal sprays or oral vaccines could generate immunity in the wet surfaces of the nose, throat, lungs and digestive tract, potentially providing ten times more protection.
Chapter 8
Practice Makes Prepared: Simulating Pandemic Response
In 2015, a Pulitzer-winning New Yorker article warned that the Cascadia Subduction Zone could trigger a catastrophic earthquake along the Pacific Northwest coast. With the last major quake occurring around 1700 and these events happening roughly every 243 years, the region appears overdue. The federal government runs periodic Cascadia Rising exercises involving thousands of participants from government agencies, military, nonprofits, and businesses. While these simulations haven't yet led to comprehensive retrofitting of buildings due to prohibitive costs, they at least focus attention on this looming threat.
In disaster preparation, terminology matters. A drill tests just one system component, like whether a fire alarm works and people evacuate properly. More complex is the tabletop exercise-a discussion identifying and solving problems. Even more sophisticated is the functional exercise, simulating a disaster to test the entire system without actually moving people or equipment. Finally, full-scale exercises like Cascadia Rising aim to replicate reality completely, with actors portraying victims and actual movement of people and equipment.
Despite their importance, there have been surprisingly few full-scale exercises testing the world's ability to detect and respond to disease outbreaks. While tabletop and functional exercises for outbreaks exist, only a handful of country-scale simulations for flu or coronavirus have been conducted. Indonesia ran the first in Bali in 2008, but no exercises have involved entire global regions. Vietnam stands out positively with frequent simulations that prepared them well for COVID, while other countries' exercises often end with unheeded recommendations.
America's outbreak simulation history reveals consistent failures to implement needed changes. The UK's Cygnus exercise (2016) highlighted government readiness problems that went unaddressed before COVID. The U.S. Crimson Contagion exercise in 2019 revealed systemic failures: unclear federal authority, insufficient vaccine funding, poor state coordination, and communication problems. Earlier simulations like Dark Winter (2001), Atlantic Storm (2005), and Event 201 (2019) all identified major preparedness gaps, but recommendations were largely ignored.
Future full-scale exercises should simulate city outbreaks that could spread globally, testing diagnostic development, public communication, quarantine implementation, and responses to supply chain disruptions. They should include case reporting systems, genetic sequencing, and volunteers testing non-pharmaceutical measures. Unlike previous exercises whose findings were forgotten, these must drive real policy changes.
Since pandemic risk exceeds war risk, GERM should organize global exercises at least once per decade, with regions conducting additional simulations. The COVID experience has made such exercises more relevant than ever, as countries that experienced SARS in 2003 responded better to COVID-19, showing how real experience drives preparedness.
Bioterrorism presents an even more unsettling threat than natural outbreaks. From Frederick I poisoning wells in 1155 to the 2001 anthrax mail attacks, weaponized pathogens have a long history. Smallpox, with its high mortality rate and airborne transmission, would be particularly devastating since most people lack immunity after vaccination programs ended in 1980. The risk has increased as bioweapon knowledge spread beyond government labs following the Soviet Union's collapse, with college students now able to learn the necessary techniques. Given the catastrophic potential, more defense funding should support disease research, and governments should consider offering substantial rewards for information preventing bio-attacks.
Chapter 9
Closing the Global Health Gap
The world's COVID response revealed stark inequities in vaccine distribution. While higher-income countries administered millions of doses by January 2021, one lowest-income country had received just 25 doses. By July 2021, 50% of Americans were fully vaccinated compared to just 7% in India and under 6% in South Africa. However, global health workers recognize that COVID inequities, though shocking, aren't unique or even the worst in global health. Over the past decade, 24 million women and babies died during childbirth in developing countries, intestinal diseases killed 19 million, HIV killed nearly 11 million, and malaria over 7 million.
The COVID response benefited from global health infrastructure built over decades. When scientists needed to understand the virus through genetic sequencing, several African countries-particularly South Africa and Nigeria-were better prepared than the United States, having developed robust sequencing lab networks originally intended for local diseases. These labs pivoted quickly to COVID work and were first to discover both the Beta and Omicron variants.
When COVID struck, poor countries needed preventive equipment like masks and oxygen but struggled to acquire them. The Global Fund-created in 2002 to fight HIV, TB, and malaria-stepped in with its established delivery systems and financing mechanisms. The Fund, which normally distributes nearly 190 million malaria-preventing bed nets annually and provides HIV medicines to 22 million people, quickly raised almost $4 billion for COVID response.
Countries with recent polio campaign experience had another advantage: emergency operations centers (EOCs). Pakistan repurposed its polio infrastructure for COVID response, converting its EOC and retraining 6,000 polio surveillance workers to monitor for COVID symptoms. The polio call center became a COVID information hotline, while staff shifted to tracking cases and coordinating contact tracing. By late 2021, Pakistan was vaccinating 2 million people daily-an exceptional rate for a lower-middle-income country.
Global health funding is surprisingly modest compared to its impact. In 2019, development assistance for health totaled $40 billion annually, rising to $55 billion in 2020 with COVID response-just 0.005% of global economic output, roughly equivalent to annual global perfume spending. The United States contributes about $7.9 billion yearly, less than 0.2% of the federal budget. This relatively small investment has driven remarkable progress-child deaths under age five dropped from 10 million in 1990 to just over 4 million by 2019, with dramatic reductions in deaths from pneumonia, diarrheal diseases, measles, malaria, and nutritional deficiencies.
Chapter 10
A Comprehensive Plan for Preventing Future Pandemics
We must act now while the memory of COVID remains fresh, or risk pandemic prevention being pushed to the back burner once the crisis subsides. The next pandemic may look nothing like COVID-it could affect different age groups, spread differently, or be both deadlier and more infectious. It might even be designed by humans as a bioterror attack. What's missing in most countries isn't scientific capability but a concrete plan with clear responsibilities for research, monitoring, testing ideas, and ensuring rapid mass manufacturing.
Innovation doesn't happen automatically-it requires sustained investment. We must continue developing better vaccines, therapeutics, and diagnostics, including approaches beyond mRNA vaccines that might provide longer protection or target parts of viruses unlikely to mutate. Our ultimate goal should be vaccines that protect against entire virus families, especially respiratory viruses. We also need infection-blocking drugs people can self-administer for immediate protection, improved clinical trial protocols ready before outbreaks occur, and manufacturing capacity to provide vaccines globally within six months of identifying a new pathogen.
Creating the Global Epidemic Response and Mobilization team will take years, requiring resources and proper staffing from wealthy governments. Though many organizations can advise on GERM's design, its annual budget needs to come almost entirely from wealthy nations and be managed through WHO as a global resource. Alongside GERM, we must invest more in public health infrastructure-not just doctors and clinics, but epidemiologists and specialists who conduct disease surveillance and guide political leaders during crises.
Disease surveillance is finally getting the attention it deserves after years of neglect. Low and middle-income countries need stronger birth and death registries as a foundation, then must expand into genomic sequencing, minimally invasive autopsy sampling, and wastewater surveillance. The goal is enabling every country to detect and respond to outbreaks within their borders. Globally, disparate surveillance systems must be integrated to rapidly detect respiratory viruses wherever they emerge, using both active and passive approaches with real-time data sharing.
When COVID struck, crucial advances in vaccines came from academics and companies in the UK and Germany, accelerated by funding from high-income countries-particularly the United States. Now governments must continue leading with new funding for pandemic prevention systems. The GERM team will require roughly $1 billion per year from wealthy and middle-income nations. Over the next decade, governments need to collectively spend $15-20 billion annually on vaccines, infection-blocking drugs, treatments, and diagnostics.
This investment makes everyone safer, creates foundations for growth, helps countries escape poverty, and is morally right. The opposite of complacency isn't fear-it's action. We have an unprecedented opportunity not just to prevent another global catastrophe but to work toward a world where everyone has a chance at a healthy, productive life.
Climate change and pandemics are the most likely existential threats facing humanity, but there's good news: we can make major progress on both within the next decade. While avoiding climate disaster requires massive investment, pandemic preparedness needs comparatively less funding yet can develop most necessary tools within ten years. Everyone can contribute by electing leaders who take pandemics seriously, following public health guidance, getting vaccinated, and avoiding misinformation. By investing billions now, we can prevent losing millions of lives and trillions of dollars in the future.
